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Summary
The importance of vitamin A for host defense is undeniable and the study of its mechanisms is 
paramount. Of the estimated 250 million preschool children who are vitamin A deficient (VAD), 
10% will die from their increased susceptibility to infectious disease. Vitamin A supplementation 
was established in the 1980s as one of the most successful interventions in the developing world. 
Understanding how Vitamin A controls immunity will curb the mortality and morbidity associated 
with VAD and exploit the immune enhancing capacity of vitamin A to heighten host resistance to 
infectious disease. The discoveries that retinoic acid (RA) imprints the homing of leukocytes to 
the gut and enhanced the induction of regulatory T-cells highlighted a potential role for RA in 
mucosal tolerance. However, emerging data tells of a more profound systemic impact of RA on 
leukocyte function and commitment. In animal models using genetic manipulation of RA 
signaling, we learn when and how RA controls T-cell fate. Here we review the role for RA as a 
critical checkpoint regulator in the differentiation of CD4+ T-cells within the immune system.
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Introduction
Vitamin A through its active derivative retinoic acid (RA), plays a critical role in 
embryogenesis, determining cell lineage and fate commitment [1]. In areas where 
malnutrition is endemic, vitamin A deficient (VAD) children have a severe impairment in 
vision due to the critical role of RA in the retina, to which it owes its name. In addition, 
VAD is associated with an increased burden of infectious disease [2], highlighting the 
importance of vitamin A for immunity. The pivotal discovery that RA was constitutively 
synthesised by gut dendritic cells was closely followed by several studies showing that RA 
was able to enhance induction of inducible regulatory T cells (iTreg). These findings led to 
the view that RA might act to promote oral tolerance and shifted the attention away from the 
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critical nature of RA in peripheral, effector immune responses. In recent years a broader role 
for RA in systemic immunity has re-emerged. Several studies have demonstrated regional 
induction of RA synthesis and signaling upon inflammation [3],[4], and RA has been shown 
to play an essential role in Th1 responses in allograft rejection, vaccination and gut infection 
[4],[5]. In this review we focus on these recent advances that have shed light on a broader 
role for RA in directing T-helper cell fate, outside of the mucosal immune system. Given the 
clinical availability of retinoids, their mechanisms of action and emerging roles as 
immunotherapeutic agents will be discussed.
Retinoic acid: Beyond mucosal immunity
Multiple isoforms of RA exist. Of these all-trans retinoic acid (ATRA) is the predominant 
biological form and is the subject of this review. RA is generated from retinol, which 
circulates in the plasma bound to retinol binding protein. RA synthesis is restricted to cells 
that express the enzymes required for conversion of retinol to RA. First, retinol is converted 
to retinal by retinol dehydrogenase (RDH). Studies in rdh10−/− mice suggest that RDH10 is 
the critical isoform for retinal synthesis [6]. Retinal is then irreversibly converted to RA by 
one of three retinaldehyde dehydrogenase isoforms: RALDH1, RALDH2 or RALDH3 
encoded by aldh1a1, aldh1a2, and aldh1a3, respectively [7],[8].
A role for RA in mucosal immunity was established by the discovery that dendritic cells 
within the mesenteric lymph node (MLN) and Peyer’s patches (PP) constitutively express 
aldh1a2, the gene that encodes RALDH2, and that RA could imprint gut tropism on T-cells 
through the induction of gut-homing receptors, CCR9 and α4β7 [9]. Within both human and 
murine MLNs, DCs that express the highest levels of aldh1a2 are the CD103+ subset [10],
[11]. Recently it was shown that expression of 4-1BB, a member of the TNF receptor 
superfamily, correlates with CD103 positivity in dendritic cells and 4-1BB is therefore also 
able to identify MLN DCs with the highest levels of aldh1a2 [12]. Triggering of 4-1BB 
induced RALDH activity in vitro and 4-1BB deficient MLN DCs have weak RALDH 
activity pointing to a functional role for 4-1BB in the induction of RA synthesis.
Outside of the gut, examination of peripheral DC subsets have identified DCs expressing 
aldh1a2 residing in the lung and skin, pointing to a role for RA in steady state immune 
responses at barrier sites [13],[14]. Although the majority of peripheral DCs express 
negligible or low levels of RALDH, the identification of cytokines and pathogen-associated 
molecular patterns that can induce RALDH expression indicates that RA synthesis and 
signaling may be a widespread occurrence during the course of a peripheral immune 
response. Treatment of splenic DCs with zymosan, a TLR-2 agonist, results in the induction 
of aldh1a2 in vitro, and stimulation of WT but not TLR2−/− splenic DCs with Candida 
albicans has a similar effect [15]. In vitro, GM-CSF can induce both bone marrow-derived 
DCs and splenic DCs to express aldh1a2 [16].
Several in vivo studies have now demonstrated local induction of RALDH activity amongst 
DCs in response to a diverse array of inflammatory stimuli including viral infection, 
alloantigen and tumour burden [3],[17],[4],[18],[19]. In addition to RA synthesis by DCs, 
upregulation of aldh1a2 expression has been observed in alternatively activated 
macrophages following infection with the helminth Shistosoma mansoni [20]. These studies 
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suggest that RA synthesis and signaling may be a universal feature of immune responses 
both in the gut and the periphery. Intriguingly, peripheral induction of T and B-cell 
responses in the presence of RA still leads to induction of gut homing receptors [17],[21]. 
Induction of CCR9 expression on lung derived CD4+ T-cells following intranasal influenza 
infection resulted in trafficking of these cells to the small intestine. Local production of IFN-
γ resulted in alterations to the gut microbiota which in turn led to increased numbers of 
intestinal Th17 cells. These findings explain the incidence of intestinal side effects observed 
in influenza patients but the functional relevance of gut homing to the primary immune 
response remains to be determined. Recent discoveries have shown that systemic immune 
responses at sites distal to the gut are modulated through the gut microbiota [22],[23] and it 
is possible that lymphocyte trafficking through the gut is a necessary rite of passage for 
effector T-cells. Regional RA production at peripheral sites of inflammation with 
subsequent induction of gut homing properties on lymphocytes may play a key role in 
shaping the course of the immune response.
RA regulation of T-helper cell fate and plasticity
RA enhances Foxp3 expression and stability
Following the initial study that identified RA synthesis by gut DCs, several groups went on 
to show that RA could dramatically enhance the TCR-TGF-β-mediated conversion of naïve 
CD4+ T cells to induced regulatory T-cells (iTreg) in vitro [10],[24],[25]. TGF-β mediated 
Foxp3 induction is dependent on Smad3 [26],[27]. In addition to directly regulating the 
expression of Smad3 [28], RA regulation of Foxp3 expression is in part mediated by binding 
of RAR/RXR heterodimers to a RA response element (RARE) in the enhancer 1 (CNS1) 
region of the Foxp3 gene, which facilitates binding of phosphorylated Smad3 to the 
enhancer region [29]. The first in vivo evidence supporting a role for the RA/TGF-β-Smad3 
pathway in the generation of peripheral Tregs (pTreg) in the GALT comes from a recent 
study utilising mice lacking the Smad3 binding site within the CNS1 region. Aged mice 
develop deficiencies in Foxp3+ cells in the LP and PP; however, the functional significance 
of this is unclear since no negative impact of the pTreg deficiency was observed in T-
independent or T-cell dependent models of colitis [30]. Further studies are required to 
understand the in vivo contribution of RA to immune tolerance, both in the gut as well as at 
peripheral sites of immune responses.
In addition to enhancing TCR-TGF-β mediated Foxp3 expression, RA has also been shown 
to confer increased stability of Foxp3 expression in the face of inflammatory cytokines and 
co-stimulation amongst both iTreg and thymic Treg (tTreg) [24],[28] [31]. iTregs generated 
in the presence of RA express reduced levels of the receptor for IL-6, a Th17 instructing 
cytokine [32]. Recently, RA and TGF-β were shown to induce expression of the microRNA 
miR-10a, which in turn inhibited expression of the follicular helper T-cell (TFH) master 
transcription factor, Bcl-6 [33]. Conversion of Tregs to TFH has been described in PP [34], 
and miR10-a overexpression in iTregs was able to reduce this conversion in vivo [33]. RA 
may therefore reinforce lineage stability by regulating opposing pathways that instruct 
alternative T-helper cell fates.
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A newly described role for RA in the conversion of CD4+ T-cells to CD4+CD8αα+ T-cells 
within the intestinal epithelium provides a further mechanism by which RA promotes anti-
inflammatory responses within the gut [35]. Cd4creRosa26dnRara/dnRara mice conditionally 
expressing a dominant negative form of the retinoic acid receptor RARα (dnRara) in CD4+ 
T-cells (henceforth referred to as dnRara mice) have severely impaired numbers of 
CD4+CD8α+ IELs, which appear to play a critical role in preventing intestinal 
inflammation. dnRara expressing CD4+ T-cells fail to upregulate T-bet, which in turn 
directs the expression of the CD8 lineage transcription factor, Runx3, and inhibits ThPok 
allowing reprogramming of CD4+ cells towards CD8α+ IELs.
Retinoic acid is critical for CD4+ effector T-cell differentiation
A role for RA in the generation of Tregs seemed counterintuitive given the wealth of 
epidemiological data supporting a role for RA in immunity to infectious disease. Emerging 
data examining the effects of RA on effector lymphocytes in vivo have gone someway to 
resolving this paradox by demonstrating a broader role for RA in Th-cell responses (Fig. 2). 
Our own studies using dnRara mice demonstrate a critical role for RA in the development of 
Th1 mediated immunity in a model of allograft rejection [4],[5]. In keeping with the ability 
of RA to regulate Th1 differentiation, VAD mice infected with Toxoplasma gondii were 
found to have significantly reduced Th1 cells in their GALT and spleen [5]. In the same 
study, VAD mice were also shown to have deficient Th1 cell responses in response to 
vaccination with ovalbumin (OVA) and E. coli toxin [5].
The molecular mechanism through which RA controls Th1 cell fate remains unclear. In vitro 
experiments conducted with CD4+ T cells isolated from RARα−/− mice suggest that 
disruption of RA signaling leads to impaired activation induced proliferation[5]. However, 
dnRara expressing CD4+ T-cells mice have normal proliferative capacity [4]. One possible 
explanation for this discrepancy is that unliganded RARs inhibit transcription through 
recruitment of co-repressors [36], thus deletion of RARα may lead to a loss of inhibition of 
RAR targets with a paradoxical up-regulation of RA target genes in the absence of RA. In 
zebrafish, deletion of RAR isoforms resulted in a paradoxical increase in RA signaling with 
compensatory increases in expression of alternative RARs [37]. RARα does appear to be the 
critical receptor in mediating the effects of RA on CD4+ T-cells as deletion of RARγ in 
haematopoietic cells had no impact on the development of Th1 responses following 
infection with Listeria monocytogenes [38]. Analysis of RARα target genes in Th1 cells will 
shed light on the transcriptional regulation of Th1 program by RA. In contrast to a 
physiological role for RA in supporting Th1 differentiation, RA treatment of naive CD4+ T-
cells polarised under Th1 conditions in vitro inhibits IFN-γ production [39].
In addition to shaping Th1 responses, RA has also been shown to regulate Th17 
differentiation. The earliest studies linking RA to TGF-β mediated Foxp3+ expression 
identified a reciprocal role for RA in the inhibition of Th17 cells differentiated from naïve 
T-cells with TGF-β and IL-6 in vitro. This appears to be in part due to reduced expression of 
IL-6R and IL-23R in responder T-cells [28]. Interestingly, the inhibitory effects of RA on 
Th17 differentiation are most prominent in the presence of IL-2 [33]. IL-2 activation of 
Stat5 antagonises Stat3 and RA inhibition of Th17 differentiation is dependent on Stat5 [28],
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[33]. Consistent with these in vitro findings, RA administration in vivo inhibits the 
development of Th17 responses and disease severity in experimental autoimmune 
encephalitis (EAE), a Th17 mediated autoimmune disease [28]. While pharmacological 
doses of RA inhibit Th17 generation, physiological levels of RA (<10nm), have been shown 
to enhance Th17 generation in vitro [33]. In support of an in vivo role for RA in the 
generation or maintenance of Th17 cells, studies in VAD mice describe a near absence of 
Th17 cells both during homeostasis and in response to immune-mediated inflammation [5],
[40]. However, two recent studies have identified a role for RA in the generation of a type 3 
innate lymphoid cells (ILC3s),, which mirror Th17 cells in their cytokine profile. VAD mice 
and mice treated with an RA antagonist had impaired ILC3 responses both in steady state 
and in response to intestinal infection with Citrobacter rodentium [41]. ILC3s produce Th17 
associated cytokines and their absence in VAD mice may contribute to the impaired 
development of Th17 cells at the mucosal surface. Further studies are required in 
CD4creDNRAR mice to establish the role of RA in Th17 generation in vivo.
The absence of ILC3s in VAD mice has widespread implications on adaptive immune 
responses since a subset of ILC3s, lymphoid tissue inducer (LTi) cells play a critical role in 
the development of secondary lymphoid organs and Peyer’s patches. Maternal vitamin A 
and fetal RA signaling were found to directly regulate the expression of RORγt, instructing 
the development of LTis [42]. Mice exposed to an RA-deficient environment in utero had 
smaller secondary lymphoid organs which persisted in adult life with impaired adaptive 
immune responses. Since many earlier studies have used VAD as a model for studying RA 
regulated dynamic T-cell responses, these studies must be reevaluated in light of the 
widespread homeostatic defects observed in these mice.
In addition to Th1 and Th17 mediated immune responses, RA synthesis has been reported in 
parasite infections suggesting a possible role for RA in shaping Th2 responses. Dietary VA 
levels have been shown to affect Th2 responses with enhanced production of Th2-associated 
cytokines and concomitant reduction in IFN-γ observed in CD4+ T cells isolated from 
Trichinella spiralis infected VAD mice [43]. However, in a further twist, the earlier study 
examining ILC dysregulation, VAD induced expansion of ILC2s with enhanced ILC2 
derived Th2 type cytokines [41]. The presence of ILC2s appears to be critical for Th2 
allergen responses in vivo [44], thus previously reported effects of dietary RA on Th2-cell 
responses in VAD mice may not be due to direct effects of RA on T-cells. Studies in which 
RA levels are manipulated through administration of RA are conflicting with both enhanced 
and reduced Th2 responses reported in murine models of asthma following RA treatment 
[45],[46] Genetic approaches that allow one to dissect the impact of RA signaling on defined 
lineages of hematopoietic cells and the ensuing immune responses will help to clarify the 
physiological role of RA in the regulation of Th2 mediated immunity.
Retinoic acid: an immune morphogen?
Given that the RA-RARα axis is a highly conserved signaling pathway, which plays a 
critical role in regulating cell fate specification during embryogenesis and cell 
differentiation, it is perhaps not surprising that RA has been implicated in all aspects of T-
helper cell differentiation. Pleiotropic roles for RA in the generation of Treg, Th1, Th17, and 
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Th2 cells are not mutually exclusive but rather suggest context dependent actions. The key 
to therapeutic targeting of the RA signaling pathway is an understanding of the dominant 
action of RA on T-cell specification in different in vivo settings. RA appears in part to alter 
the sensitivity of cells to alternative cell fates through regulation of cytokine receptors. Thus 
the dominant effects of RA may well be dependent on the instructive cytokine milieu. In this 
model, rather than specifying T-cell fate, RA enhances or stabilizes the actions of cytokines 
and transcription factors that guide T-helper cell programming. In this way, synthesis of RA 
by APCs provides an additional checkpoint for stabilisation of T-cell fate commitment.
An alternative model is that, similar to the morphogenic properties of RA during 
embryogenesis, the RA concentration sensed by naïve T-cells undergoing differentiation 
determines the dominant action of RA on T-cell fate. Over the past few years, RA has 
achieved recognition as a morphogen, as it has become clear that synthesis and metabolism 
of RA is tightly controlled resulting in concentration dependent effects on target tissues [47]. 
The preponderance of data from in vitro experiments in which dose titration comparisons 
were performed on Th1, Th2 and Th17 polarisation suggest similar dose dependent effects 
of RA on haematopoietic cell fate [33],[39],[48]. The paradoxical effects of RA on opposing 
T-cell fates may therefore be explained by concentration dependent effects of RA, allowing 
T-cells to act as an environmental sensor through the strength of its RA signal. Further 
studies of RA gradients within lymphoid tissue are required to test this hypothesis. However, 
the overriding message is that administration of RA either in vitro or to vitamin A replete 
hosts in vivo may not provide insight into the physiological actions of RA on T-cell 
responses.
A further layer of complexity surrounds RA regulation of Th-cell fate with bi-phasic effects 
of RA on Th1 and Th2 differentiation reported in vitro [39]. In Th1 differentiation, 
induction of T-bet is dependent on IFN-γ-Stat1 signaling whereas maintenance of T-bet 
expression is dependent on IL12-Stat4 activation [49], suggesting distinct roles for RA in 
the regulation of these signaling pathways. Similarly, a bi-phasic model for Th17 
differentiation is emerging with early commitment dependent on TGF-β and IL-6 signaling 
but maintenance and stability dependent on IL-21 and IL-23 signaling [50]. Animal models 
which allow temporal control of RA signaling will be invaluable for dissecting out the role 
of RA in early vs. late phase differentiation.
Retinoic acid signaling: novel mechanisms of transcriptional regulation
All-trans RA, the biologically active form of VA, signals through heterodimers of the RA 
receptors (RARs) and retinoid X receptors (RXRs) [51]. These receptors belong to the 
nuclear hormone receptor family. There are three isotypes for both RAR and RXR: α, β and 
γ. RAR/RXR heterodimers bind to RA response elements RAREs in target genes and act as 
ligand dependent transcription factors. RAR/RXRs mediate transcriptional regulation 
through the binding of co-repressor or co-activator complexes dependent on the presence of 
ligand (Fig. 1). The widely accepted view is that unliganded RAR/RXR heterodimers inhibit 
transcription of their target gene, through recruitment of co-repressors such as NCoR or 
SMRT. Binding of ligand to RAR leads to release of co-repressors and recruitment of co-
activators such as p300 and CBP with subsequent transcriptional activation of the target 
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gene [52]. In addition, RA can mediate gene repression through recruitment of ligand-
dependent co-repressors, such as RIP140 and PRAME, which recruit histone deacetylases to 
RAR/RXR complexes to repress their activities [53],[54]. RARs can also modulate 
transcription indirectly, through inhibition of transcription factor complexes, such as 
activating protein-1 (AP-1) although the underlying mechanisms remains uncertain [55].
In addition to its classical role as a transcriptional regulator, recent studies in embryonic 
stem cells have identified RA-RARα as an epigenetic regulator. Retinoids have been shown 
to regulate epigenetic changes including histone modifications and DNA methylation 
through the recruitment of co-activators with chromatin modifying properties [56]. p300, for 
example, possesses histone acetyltransferase activity and mediates acetylation of H3k27, a 
marker of active cis-regulatory regions. Epigenetic modifications have been suggested to be 
the determinants of lineage stability. Given the emerging data implicating RARα in lineage 
plasticity,, it will be important to evaluate a role for RA-RARα in the regulation of the 
epigenome. Recent studies have shed light on non-genomic actions of RAR [57]. In 
neuronal dendrites it has been shown that RARα can bind directly to mRNA, where, 
unliganded, it inhibits translation [58]. Binding of RA to its receptor leads to dissociation of 
RARα from the mRNA and relief of translational repression. In addition, RA has also been 
shown to activate mitogen activated protein kinases (MAPK) in a number of cell types [57]. 
This occurs within minutes of administration suggesting direct activation rather than 
transcriptional regulation [59]. Activation of p38MAPK leads to phosphorylation of RARα 
present in the membrane and cytosol, which in turn promotes recruitment of RAR to 
promoter regions of target genes. In this way, RA is able to link events at the cell membrane 
to its transcriptional regulation. Intriguingly, TCR-ligation and subsequent T-cell activation 
is required to observe RA mediated effects on lymphocytes and this non-classical pathway 
of RA signaling may play a key role in linking T-cell activation to subsequent 
transcriptional regulation by RA-RAR. However, at this stage, little is known about the 
importance of the non-genomic actions of RA relative to its classical regulation of 
transcription in haematopoietic cells. In other cell types studied, only a small fraction of 
RAR is available for non-genomic activities [57], suggesting that non-transcriptional 
activities of RA play a minor role in its overall activities.
In addition to signaling through RARs, RA is also a ligand for the nuclear receptor PPARβ 
(formerly PPARδ). Targeting of RA to RAR or PPARβ/δ is mediated by the cytosolic lipid 
binding proteins CRABP-II and FABP5 respectively. RA has a far greater affinity for 
CRABP-II and as such RA signaling through RAR is likely to be the dominant signaling 
pathway. However in cells that express high ratio of FABP5/CRABP-II, activation of 
PPARβ/δ is observed. Two recent studies, in adipocytes and neuronal stem cells, 
respectively, have shown that differentiation is accompanied by a fall in CRABP-II levels 
and concurrent up-regulation of FABP5 with a shift towards the RA-PPARβ signaling 
pathway [60],[61]. Thus both the PPARβ/δ and RAR signaling pathways can play important 
roles in a single cell lineage and the relative contributions of the two pathways must be 
explored in a temporal fashion. Lymphocytes express PPARβ/δ although until recently little 
was known about its function [62]. CD4+ T-cells deficient in PPARβ/δ have enhanced 
proliferative capacity and a greater propensity for IFN-γ and IL-17 production in vitro 
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suggesting that PPARβ/δ acts to restrain Th1 and Th17 differentiation [63]. In keeping with 
this, PPARβ/δ−/− mice develop a more severe form of experimental autoimmune 
encephalomyelitis (EAE) which is associated with enhanced Th1 and Th17 CNS infiltration 
[63].
IMMUNOTHERAPY WITH RETINOIDS
Retinoids as immunosuppressive agents
Topical and oral retinoids have long been used in the treatment of psoriasis with presumed 
benefit related to their effects on keratinocyte differentiation and proliferation. 
Accumulating evidence has implicated the Th17 pathway in the pathogenesis of psoriasis 
[64],[65], and it may be that the therapeutic effect of retinoids in psoriasis are related to their 
immunoregulatory effects. The ability of RA to induce Tregs in vitro, coupled with the 
suppression of Th1 and Th17 responses observed with high dose retinoids, points to a 
potential role for retinoids as immunosuppressive agents. In support of this, retinoids have 
been shown to ameliorate disease in two mouse models of SLE [66],[67]. Reduction in 
disease was associated with inhibition of Th1 responses. RA treatment has also been shown 
to significantly reduce the incidence of diabetes in a spontaneous mouse model of type 1 
diabetes (NOD) with established insulitis [68]. Adoptive transfer of NOD splenocytes into 
NOD/scid recipients leads to onset of diabetes following infiltration of the pancreas by Th1, 
Th17 and IFN-γ+ CD8+ T-cells. Treatment of recipient mice with RA inhibits the 
development of Th1 responses with a reciprocal increase in islet infiltrating Tregs [68]. 
Retinoids have also shown beneficial effect in mouse models of rheumatoid arthritis [69],
[70]. A reduction in disease severity was associated with reduced IL-17 and IL-21 levels 
within the synovial fluid as well as reduced antibody production [70]. A limitation to current 
retinoid therapy is the adverse toxicity profile and off target effects of pan RAR agonists. 
Agonists selective for RARα, the isotype, implicated in effector T-cell responses, are 
currently in clinical development.
One possible future use for retinoids is the ex vivo generation of stable Tregs for cellular 
immunotherapy in the context of autoimmune disease and transplantation. The stability of ex 
vivo expanded Tregs has been a significant concern. RA treatment of Tregs has been shown 
to constrain their plasticity within an inflammatory setting and RA treatment could be 
incorporated into protocols for Treg expansion. RA mediated induction of CCR9 and α4β7 
may also generate Tregs with enhanced capacity for gut homing which could be 
advantageous in the setting of inflammatory bowel disease.
Concluding remarks
Recent advances have led to an increased understanding of why VA is so critical for 
immunological health and has extended the importance of this vitamin beyond the 
malnourished patient. Given the pleiotropic effects of RA, the challenge for successful 
immunotherapy will rely on a detailed understanding of the molecular mechanisms through 
which RA receptors mediate their effects, opening the door for new immunomodulatory 
drugs.
Brown and Noelle Page 8
Eur J Immunol. Author manuscript; available in PMC 2016 May 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Acknowledgments
This work was supported the Wellcome Trust (Research Training Fellowship to CB and Program Grant to RJN) 
and the NIH (R01AT005382 to RJN).
References
1. Niederreither K, Dollé P. Retinoic acid in development: towards an integrated view. Nature Reviews 
Genetics. 2008; 9:541–553.
2. Sommer A, Djunaedi E, Loeden AA, Tarwotjo I, West K JR, Tilden R, Mele L, et al. Impact Of 
Vitamin A Supplementation on Childhood Mortality. The Lancet. 1986; 327:1169–1173.
3. Guo Y, Pino-Lagos K, Ahonen CA, Bennett KA, Wang J, Napoli JL, Blomhoff R, et al. A Retinoic 
Acid--Rich Tumor Microenvironment Provides Clonal Survival Cues for Tumor-Specific CD8+ T 
Cells. Cancer Res. 2012; 72:5230–5239. [PubMed: 22902413] 
4. Pino-Lagos K, Guo Y, Brown C, Alexander MP, Elgueta R, Bennett KA, De Vries V, et al. A 
retinoic acid-dependent checkpoint in the development of CD4+ T cell-mediated immunity. Journal 
of Experimental Medicine. 2011; 208:1767–1775. [PubMed: 21859847] 
5. Hall JA, Cannons JL, Grainger JR, Santos Dos LM, Hand TW, Naik S, Wohlfert EA, et al. Essential 
Role for Retinoic Acid in the Promotion of CD4+ T Cell Effector Responses via Retinoic Acid 
Receptor Alpha. Immunity. 2011; 34:435–447. [PubMed: 21419664] 
6. Napoli JL. Physiological insights into all-trans-retinoic acid biosynthesis. Biochim Biophys Acta. 
2012; 1821:152–167. [PubMed: 21621639] 
7. Niederreither K, Subbarayan V, Dollé P, Chambon P. Embryonic retinoic acid synthesis is essential 
for early mouse post-implantation development. Nat Genet. 1999; 21:444–8. [PubMed: 10192400] 
8. Lin M, Zhang M, Abraham M, Smith SM. Mouse retinal dehydrogenase 4 (RALDH4), molecular 
cloning, cellular expression, and activity in 9-cis-retinoic acid biosynthesis in intact cells. J Biol 
Chem. 2003; 278:9856–61. [PubMed: 12519776] 
9. Iwata M, Hirakiyama A, Eshima Y, Kagechika H, Kato C, Song S-Y. Retinoic acid imprints gut-
homing specificity on T cells. Immunity. 2004; 21:527–538. [PubMed: 15485630] 
10. Coombes J, Siddiqui K, Arancibia-C C. A functionally specialized population of mucosal CD103+ 
DCs induces Foxp3+ regulatory T cells via a TGF-beta and retinoic acid-dependent mechanism. 
The Journal of Experimental Medicine. 2007; 204:1757. [PubMed: 17620361] 
11. Jaensson E, Uronen-Hansson H, Pabst O, Eksteen B, Tian J, Coombes JL, Berg PL, et al. Small 
intestinal CD103+ dendritic cells display unique functional properties that are conserved between 
mice and humans. Journal of Experimental Medicine. 2008; 205:2139–2149. [PubMed: 18710932] 
12. Lee S-W, Park Y, Eun S-Y, Madireddi S, Cheroutre H, Croft M. Cutting Edge: 4-1BB Controls 
Regulatory Activity in Dendritic Cells through Promoting Optimal Expression of Retinal 
Dehydrogenase. The Journal of Immuunology. 2012; 189:2697–701.
13. Guilliams M, Crozat K, Henri S, Tamoutounour S, Grenot P, Devilard E, de Bovis B, et al. Skin-
draining lymph nodes contain dermis-derived CD103- dendritic cells that constitutively produce 
retinoic acid and induce Foxp3+ regulatory T cells. Blood. 2010; 115:1958–1968. [PubMed: 
20068222] 
14. Gyöngyösi A, Szatmari I, Pap A, Dezso B, Pos Z, Széles L, Varga T, et al. RDH10, RALDH2, and 
CRABP2 are required components of PPARγ-directed ATRA synthesis and signaling in human 
dendritic cells. J Lipid Res. 2013; 54:2458–2474. [PubMed: 23833249] 
15. Manicassamy S, Pulendran B. Retinoic acid-dependent regulation of immune responses by 
dendritic cells and macrophages. Seminars in Immunology. 2009; 21:22–27. [PubMed: 18778953] 
16. Yokota A, Takeuchi H, Maeda N, Ohoka Y, Kato C, Song S-Y, Iwata M. GM-CSF and IL-4 
synergistically trigger dendritic cells to acquire retinoic acid-producing capacity. International 
Immunology. 2009; 21:361–377. [PubMed: 19190084] 
17. Wang J, Li F, Wei H, Lian Z-X, Sun R, Tian Z. Respiratory influenza virus infection induces 
intestinal immune injury via microbiota-mediated Th17 cell-dependent inflammation. Journal of 
Experimental Medicine. 2014; 211:2397–2410. [PubMed: 25366965] 
Brown and Noelle Page 9
Eur J Immunol. Author manuscript; available in PMC 2016 May 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
18. Allie SR, Zhang W, Tsai C-Y, Noelle RJ, Usherwood EJ. Critical role for all-trans retinoic acid for 
optimal effector and effector memory CD8 T cell differentiation. The Journal of Immunology. 
2013; 190:2178–2187. [PubMed: 23338237] 
19. Mielke LA, Jones SA, Raverdeau M, Higgs R, Stefanska A, Groom JR, Misiak A, et al. Retinoic 
acid expression associates with enhanced IL-22 production by γδ T cells and innate lymphoid cells 
and attenuation of intestinal inflammation. Journal of Experimental Medicine. 2013; 210:1117–
1124. [PubMed: 23690441] 
20. Broadhurst MJ, Leung JM, Lim KC, Girgis NM. Upregulation of Retinal Dehydrogenase 2 in 
Alternatively Activated Macrophages during Retinoid-dependent Type-2 Immunity to Helminth 
Infection in Mice. PLoS Pathog. 2012; 8:e1002883. [PubMed: 22927819] 
21. Hammerschmidt S, Friedrichsen M, Boelter J. Retinoic acid induces homing of protective T and B 
cells to the gut after subcutaneous immunization in mice. J Clin Invest. 2011; 121:3051–3061. 
[PubMed: 21737878] 
22. Wu H-J, Ivanov II, Darce J, Hattori K, Shima T, Umesaki Y, Littman DR, et al. Gut-residing 
segmented filamentous bacteria drive autoimmune arthritis via T helper 17 cells. Immunity. 2010; 
32:815–827. [PubMed: 20620945] 
23. Lee YK, Menezes JS, Umesaki Y, Mazmanian SK. Proinflammatory T-cell responses to gut 
microbiota promote experimental autoimmune encephalomyelitis. Proc Natl Acad Sci USA. 2011; 
108:4615–4622. [PubMed: 20660719] 
24. Benson M, Pino-Lagos K, Rosemblatt M, Noelle R. All-trans retinoic acid mediates enhanced T 
reg cell growth, differentiation, and gut homing in the face of high levels of co-stimulation. 
Journal of Experimental Medicine. 2007; 204:1765. [PubMed: 17620363] 
25. Mucida D, Park Y, Kim G, Turovskaya O, Scott I. Reciprocal TH17 and regulatory T cell 
differentiation mediated by retinoic acid. Science. 2007; 317:256–60. [PubMed: 17569825] 
26. Tone Y, Furuuchi K, Kojima Y, Tykocinski ML, Greene MI, Tone M. Smad3 and NFAT 
cooperate to induce Foxp3 expression through its enhancer. Nature Immunology. 2008; 9:194–
202. [PubMed: 18157133] 
27. Zheng Y, Josefowicz S, Chaudhry A, Peng XP, Forbush K, Rudensky AY. Role of conserved non-
coding DNA elements in the Foxp3 gene in regulatory T-cell fate. Nature. 2010; 463:808–812. 
[PubMed: 20072126] 
28. Xiao S, Jin H, Korn T, Liu SM, Oukka M, Lim B, Kuchroo VK. Retinoic acid increases Foxp3+ 
regulatory T cells and inhibits development of Th17 cells by enhancing TGF-beta-driven Smad3 
signaling and inhibiting IL-6 and IL-23 receptor expression. The Journal of Immunology. 2008; 
181:2277–2284. [PubMed: 18684916] 
29. Xu L, Kitani A, Stuelten C, McGrady G, Fuss I. Positive and negative transcriptional regulation of 
the Foxp3 gene is mediated by access and binding of the Smad3 protein to enhancer I. Immunity. 
2010; 33:313–25. [PubMed: 20870174] 
30. Schlenner SM, Weigmann B, Ruan Q, Chen Y, Boehmer von H. Smad3 binding to the foxp3 
enhancer is dispensable for the development of regulatory T cells with the exception of the gut. 
Journal of Experimental Medicine. 2012; 209:1529–1535. [PubMed: 22908322] 
31. Zhou X, Kong N, Wang J, Fan H, Zou H. Cutting Edge: All-Trans Retinoic Acid Sustains the 
Stability and Function of Natural Regulatory T Cells in an Inflammatory Milieu. The Journal of 
Immunology. 2010; 185:2675–9. [PubMed: 20679534] 
32. Hill JA, Hall JA, Sun C-M, Cai Q, Ghyselinck N, Chambon P, Belkaid Y, et al. Retinoic Acid 
Enhances Foxp3 Induction Indirectly by Relieving Inhibition from CD4+CD44hi Cells. Immunity. 
2008; 29:758–770. [PubMed: 19006694] 
33. Takahashi H, Kanno T, Nakayamada S, Hirahara K, egrave GS, Muljo SA, Kuchen S, et al. TGF-β 
and retinoic acid induce the microRNA miR-10a, which targets Bcl-6 and constrains the plasticity 
of helper T cells. Nature Immunology. 2012:1–11.
34. Tsuji M, Komatsu N, Kawamoto S, Suzuki K, Kanagawa O, Honjo T, Hori S, et al. Preferential 
generation of follicular B helper T cells from Foxp3+ T cells in gut Peyer’s patches. Science. 
2009; 323:1488–1492. [PubMed: 19286559] 
Brown and Noelle Page 10
Eur J Immunol. Author manuscript; available in PMC 2016 May 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
35. Reis BS, Rogoz A, Costa-Pinto FA, Taniuchi I, Mucida D. Mutual expression of the transcription 
factors Runx3 and ThPOK regulates intestinal CD4+ T cell immunity. Nature Immunology. 2013; 
14:271–280. [PubMed: 23334789] 
36. Kurokawa R, Söderström M, Hörlein A, Halachmi S, Brown M, Rosenfeld MG, Glass CK. 
Polarity-specific activities of retinoic acid receptors determined by a co-repressor. Nature. 1995; 
377:451–454. [PubMed: 7566126] 
37. D’Aniello E, Rydeen AB, Anderson JL, Mandal A, Waxman JS. Depletion of retinoic acid 
receptors initiates a novel positive feedback mechanism that promotes teratogenic increases in 
retinoic acid. PLoS Genet. 2013; 9:e1003689. [PubMed: 23990796] 
38. Dzhagalov I, Chambon P. Regulation of CD8+ T Lymphocyte Effector Function and Macrophage 
Inflammatory Cytokine Production by Retinoic Acid Receptor γ. The Journal of Immunology. 
2007; 178:2113–21. [PubMed: 17277115] 
39. Iwata M, Eshima Y, Kagechika H. Retinoic acids exert direct effects on T cells to suppress Th1 
development and enhance Th2 development via retinoic acid receptors. International Immunology. 
2003; 15:1017–1025. [PubMed: 12882839] 
40. Wang C, Kang SG, HogenEsch H, Love PE, Kim CH. Retinoic acid determines the precise tissue 
tropism of inflammatory Th17 cells in the intestine. The Journal of Immunology. 2010; 184:5519–
5526. [PubMed: 20400707] 
41. Spencer SP, Wilhelm C, Yang Q, Hall JA, Bouladoux N, Boyd A, Nutman TB, et al. Adaptation of 
Innate Lymphoid Cells to a Micronutrient Deficiency Promotes Type 2 Barrier Immunity. Science. 
2014; 343:432–437. [PubMed: 24458645] 
42. van de Pavert SA, Ferreira M, Domingues RG, Ribeiro H, Molenaar R, Moreira-Santos L, Almeida 
FF, et al. Maternal retinoids control type 3 innate lymphoid cells and set the offspring immunity. 
Nature. 2014; 508:123–127. [PubMed: 24670648] 
43. Cantorna MT, Nashold FE, Hayes CE. In vitamin A deficiency multiple mechanisms establish a 
regulatory T helper cell imbalance with excess Th1 and insufficient Th2 function. J Immunol. 
1994; 152:1515–1522. [PubMed: 8120366] 
44. Halim TYF, Steer CA, Mathä L, Gold MJ, Martinez-Gonzalez I, Mcnagny KM, McKenzie ANJ, et 
al. Group 2 Innate Lymphoid Cells Are Critical for the Initiation of Adaptive T Helper 2 Cell-
Mediated Allergic Lung Inflammation. Immunity. 2014; 40:425–435. [PubMed: 24613091] 
45. Schuster GU, Kenyon NJ, Stephensen CB. Vitamin A deficiency decreases and high dietary 
vitamin A increases disease severity in the mouse model of asthma. J Immunol. 2008; 180:1834–
1842. [PubMed: 18209081] 
46. Wu J, Zhang Y, Liu Q, Zhong W, Xia Z. All-trans retinoic acid attenuates airway inflammation by 
inhibiting Th2 and Th17 response in experimental allergic asthma. BMC Immunol. 2013; 14:28. 
[PubMed: 23800145] 
47. White RJ, Nie Q, Lander AD, Schilling TF. Complex Regulation of cyp26a1 Creates a Robust 
Retinoic Acid Gradient in the Zebrafish Embryo. PLoS Biol. 2007; 5:e304. [PubMed: 18031199] 
48. Uematsu S, Fujimoto K, Jang MH, Yang B-G, Jung Y-J, Nishiyama M, Sato S, et al. Regulation of 
humoral and cellular gut immunity by lamina propria dendritic cells expressing Toll-like receptor 
5. Nature Immunology. 2008; 9:769–776. [PubMed: 18516037] 
49. Schulz E, Mariani L, Radbruch A, Höfer T. Sequential Polarization and Imprinting of Type 1 T 
Helper Lymphocytes by Interferon-γ and Interleukin-12. Immunity. 2009; 30:673–683. [PubMed: 
19409816] 
50. Basu R, Hatton RD, Weaver CT. The Th17 family: flexibility follows function. Immunological 
reviews. 2013; 252:89–103. [PubMed: 23405897] 
51. Chambon P. A decade of molecular biology of retinoic acid receptors. The FASEB Journal. 1996; 
10:940–54.
52. Nagy L, Schwabe J. Mechanism of the nuclear receptor molecular switch. Trends in biochemical 
sciences. 2004; 29:317–24. [PubMed: 15276186] 
53. Nicholson RC, Mader S, Nagpal S, Leid M, Rochette-Egly C, Chambon P. Negative regulation of 
the rat stromelysin gene promoter by retinoic acid is mediated by an AP1 binding site. EMBO J. 
1990; 9:4443–4454. [PubMed: 2176152] 
Brown and Noelle Page 11
Eur J Immunol. Author manuscript; available in PMC 2016 May 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
54. Epping MT, Wang L, Edel MJ, Carlée L, Hernandez M, Bernards R. The human tumor antigen 
PRAME is a dominant repressor of retinoic acid receptor signaling. Cell. 2005; 122:835–847. 
[PubMed: 16179254] 
55. Perissi V, Jepsen K, Glass CK, Rosenfeld MG. Deconstructing repression: evolving models of co-
repressor action. Nature Reviews Genetics. 2010; 11:109–123.
56. Gudas LJ. Retinoids induce stem cell differentiation via epigenetic changes. Semin Cell Dev Biol. 
2013; 24:701–5. [PubMed: 23973942] 
57. Rochette-Egly C, Germain P. Dynamic and combinatorial control of gene expression by nuclear 
retinoic acid receptors (RARs). Nuclear receptor signaling. 2009; 7:e005. [PubMed: 19471584] 
58. Sarti F, Schroeder J, Aoto J, Chen L. Conditional RARα knockout mice reveal acute requirement 
for retinoic acid and RARα in homeostatic plasticity. Frontiers in Molecular Neuroscience. 2012; 
5:16. [PubMed: 22419906] 
59. Masiá S, Alvarez S, de Lera AR, Barettino D. Rapid, nongenomic actions of retinoic acid on 
phosphatidylinositol-3-kinase signaling pathway mediated by the retinoic acid receptor. Mol 
Endocrinol. 2007; 21:2391–2402. [PubMed: 17595318] 
60. Berry DC, Noy N. All-trans-retinoic acid represses obesity and insulin resistance by activating 
both peroxisome proliferation-activated receptor beta/delta and retinoic acid receptor. Molecular 
and Cellular Biology. 2009; 29:3286–3296. [PubMed: 19364826] 
61. Yu S, Levi L, Siegel R, Noy N. Retinoic acid induces neurogenesis by activating both retinoic acid 
receptors (RAR) and peroxisome proliferator-activated receptor β/δ (PPARβ/δ). Journal of 
Biological Chemistry. 2012; 287:42195–42205. [PubMed: 23105114] 
62. Schote AB, Turner JD, Schiltz J, Muller CP. Nuclear receptors in human immune cells: expression 
and correlations. Molecular immunology. 2007; 44:1436–1445. [PubMed: 16837048] 
63. Dunn SE, Bhat R, Straus DS, Sobel RA, Axtell R, Johnson A, Nguyen K, et al. Peroxisome 
proliferator-activated receptor delta limits the expansion of pathogenic Th cells during central 
nervous system autoimmunity. Journal of Experimental Medicine. 2010; 207:1599–1608. 
[PubMed: 20624891] 
64. Cargill M, Schrodi SJ, Chang M, Garcia VE, Brandon R, Callis KP, Matsunami N, et al. A large-
scale genetic association study confirms IL12B and leads to the identification of IL23R as 
psoriasis-risk genes. Am J Hum Genet. 2007; 80:273–290. [PubMed: 17236132] 
65. Kagami S, Rizzo HL, Lee JJ, Koguchi Y, Blauvelt A. Circulating Th17, Th22, and Th1 cells are 
increased in psoriasis. J Invest Dermatol. 2010; 130:1373–1383. [PubMed: 20032993] 
66. Kinoshita K, Yoo B-S, Nozaki Y, Sugiyama M, Ikoma S, Ohno M, Funauchi M, et al. Retinoic 
acid reduces autoimmune renal injury and increases survival in NZB/W F1 mice. J Immunol. 
2003; 170:5793–5798. [PubMed: 12759464] 
67. Pérez de Lema G, Lucio-Cazaña FJ, Molina A, Luckow B, Schmid H, de Wit C, Moreno-Manzano 
V, et al. Retinoic acid treatment protects MRL/lpr lupus mice from the development of glomerular 
disease. Kidney international. 2004; 66:1018–1028. [PubMed: 15327395] 
68. Van Y-H, Lee W-H, Ortiz S, Lee M-H, Qin H-J, Liu C-P. All-trans retinoic acid inhibits type 1 
diabetes by T regulatory (Treg)-dependent suppression of interferon-gamma-producing T-cells 
without affecting Th17 cells. Diabetes. 2009; 58:146–155. [PubMed: 18984738] 
69. Nozaki Y, Yamagata T, Sugiyama M, Ikoma S, Kinoshita K, Funauchi M. Anti-inflammatory 
effect of all-trans-retinoic acid in inflammatory arthritis. Clinical Immunology. 2006; 119:272–
279. [PubMed: 16412693] 
70. Kwok S-K, Park M-K, Cho M-L, Oh H-J, Park E-M, Lee D-G, Lee J, et al. Retinoic acid attenuates 
rheumatoid inflammation in mice. The Journal of Immunology. 2012; 189:1062–1071. [PubMed: 
22696440] 
Brown and Noelle Page 12
Eur J Immunol. Author manuscript; available in PMC 2016 May 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Fig. 1. Retinoic acid synthesis and signaling
Retinol is taken up from the blood and oxidized first to retinal by retinol dehydrogenases 
(RDHs) and then to all-trans-retinoic acid (RA) by retinal dehydrogenases (RALDHs). 
Within the immune system, RALDH2 is the predominant isoform expressed by dendritic 
cells. Retinoic acid receptors (RARs) are nuclear hormone receptors that function as ligand-
dependent transcription factors. RARs form heterodimers with retinoid X receptors (RXRs). 
RA binds to RAR and triggers a conformational change that promotes recruitment of 
coactivator complexes to initiate transcription and modify surrounding chromatin.
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Fig. 2. Retinoic acid gradients regulate naïve CD4+ T-cells and cytokine responses in effector 
CD4+ T-cells
Retinoic acid (RA) plays a physiological role in the differentiation of naive CD4+ T-cells. 
Administration of exogenous RA often has opposing effects on T-cell polarisation and 
inhibits production of inflammatory cytokines by effector CD4+ T-cells.
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